News Related to VLDL Cholesterol

Related coverage linked through entity extraction aliases.

Lilly's Orforglipron Outperforms Oral Semaglutide in Head-to-Head Phase 3 Trial

Mar 14, 2026

Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.

Orforglipron Shows Superior Glycemic Control Over Oral Semaglutide in Type 2 Diabetes

Mar 08, 2026

Orforglipron, an oral GLP-1 receptor agonist, demonstrated greater reductions in HbA1c and body weight compared to oral semaglutide in adults with type 2 diabetes, with more patients achieving strict glycemic targets at one year.